Ticagrelor Pharmacokinetics and Pharmacodynamics in Chinese Patients with STEMI and NSTEMI Without Opioid Administration

Abstract

Introduction: The pharmacodynamics (PD) and pharmacokinetics (PK) study of ticagrelor loading dose (LD) in Chinese patients with acute coronary syndrome (ACS) without opioid administration has never been investigated. Therefore, the aim of this study was to evaluate the antiplatelet effects and the PK parameters of ticagrelor in Chinese patients with ACS without opioid administration. Methods: A sample size of 30 eligible patients with ACS were enrolled in this study. Blood samples were obtained predose and 1, 2, 4, 8, and 12 h after 180 mg LD of ticagrelor. P2Y 12 reactivity units (PRU) and plasma concentrations of ticagrelor and its two metabolites were measured.

Clopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume

“…In this study, the effect on platelet function of ticagrelor and clopidogrel in Chinese patients agreed with the ndings reported in Western populations. Although there have been several studies investigating the pharmacology and bleeding risk associated with two anti-platelet drugs among Asian populations [31][32][33][34], few studies have concentrated on their different effects on platelet function in such populations, using different PFTs including LTA and VASP test, even though only Verify Now was applied to evaluate the platelet inhibition with ticagrelor versus clopidogrel in diabetic patients after PCI in the study of Zhenyu Liu et al [35] Various kinds of PFT have been applied to monitor platelet activity in the setting of DAPT (aspirin and clopidogrel or ticagrelor) in large clinical trials. Verify Now, LTA, MEA and ow cytometry are most intensively used among those techniques.…”